UroToday10d
mCRPC with Bone Metastasis
There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...
UroToday12d
Clarity to Present COBRA and CLARIFY Abstracts at Two World-Leading Conferences
Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...
UroToday4d
Transformative or Transitional? Deciphering the Role of NIAGARA in Shaping Future Practice - Beyond the Abstract
The phase 3 NIAGARA trial has introduced promising advancements in the treatment landscape for muscle-invasive bladder cancer (MIBC). By integrating perioperative durvalumab with neoadjuvant cisplatin ...
UroToday4d
Development of point-of-care tests for urinary bladder cancer - an historic review and view to future prospectives.
Urine is an attractive biospecimen for noninvasive tests to facilitate bladder tumor diagnostics. Three different point-of-care (POC) tests based on lateral flow immunoassays (LFAs) are currently ...
UroToday4d
Impact of late effects after treatment for bladder cancer with radical cystectomy on Quality of life: a case-control study.
The gold standard when treating muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC), a procedure that holds the potential to affect the function of several pelvic organs, causing an ...
UroToday4d
Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer.
Enzalutamide is a potent second-generation antiandrogen commonly used to treat hormone-sensitive and castration-resistant prostate cancer (CRPC) patients. While initially effective, the disease almost ...
UroToday5d
Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy.
Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities.
UroToday4d
AI Allows Pre-Screening of FGFR3 Mutational Status Using Routine Histology Slides of Muscle-Invasive Bladder Cancer - Beyond the Abstract
Urothelial carcinoma (UC) of the bladder ranks among the most prevalent malignancies worldwide, with a particularly high incidence in males. A majority of patients initially present with non-muscle ...
UroToday4d
MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms.
Beyond the more common TFE3 fusion partners PRCC, ASPSCR1, and SFPQ, additional less common fusion partners of TFE3-rearranged renal cell carcinoma (RCC) have been described. Herein, we present an ...
UroToday5d
Molecular Landscape of Aggressive Histologic Subtypes of Localized Prostate Cancer.
Despite incredible progress in describing the molecular underpinnings of prostate cancer over the last decades, pathologic examination remains indispensable for predicting aggressive behavior in the ...
UroToday5d
Key Considerations for a Prostate Cancer mRNA Vaccine.
Prostate cancer has the second highest cancer mortality rate in the UK in males. Early prostate cancer is typically asymptomatic, with diagnosis at a locally advanced or metastatic stage. In addition, ...
UroToday5d
Surgical options for advanced renal cell carcinoma.
Detection of advanced renal cell carcinoma (RCC) is not uncommon, although there has been a stage migration due to frequent use of abdominal imaging allowing early detection of renal masses. Since ...